AN OVERVIEW ON RELATION BETWEEN RETINOPATHY AND MICROALBUMINURIA IN TYPE TWO DIABETES MELLITUS WITH THEIR TREATMENT & PREVENTION

The development of new drug delivery system gained more importance in the field of research in which nanotechnology is the most considered approach. The nanotechnology-based systems such as nanoparticles, nanoliposomes, niosomes, nanomicelles, nanoemulsions, nanogels, cyclodextrins, dendrimers, and quantum dots are developed as a new formulation for drug delivery. The rationale behind the nanoparticle systems is its ability to formulate a sustained, controlled release dosage form, painless, safe, non-invasive system to overcome the major barriers in the treatment of DR. Based on the nanoparticles, some approaches are exploited for more effective conveyance of drug toward the posterior segment. Thus, these advanced delivery systems progress the therapeutic efficacy of the drug and patient’s obedience and life quality. In this review, the new therapeutic treatments and their managements were discussed and methods of drug delivery to reach the posterior segment of eye. Understanding the impact of a condition from thepatient’s perspective is important, and different types of patient-reported outcomes or instruments are available to help with this. This review article summarises the current evidence on the impact of diabetic retinopathy (DR) and its associated vision impairment on patient-reported outcomes. We have included research that has used a range of outcome measures to assess the impact of DR on generic health-related quality of life, utility, vision-functioning and vision-specific quality of life. This review also offers clarification on frequently misused psychometric terminologies to help clinicians and researchers better understand the literature associated with patient-reported outcome research. Overall, the evidence suggests that DR, particularly in its vision-threatening stages, has a substantial, negative impact on the patient.